Peter Sever

47.5k total citations · 9 hit papers
193 papers, 16.8k citations indexed

About

Peter Sever is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Peter Sever has authored 193 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Cardiology and Cardiovascular Medicine, 62 papers in Surgery and 46 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Peter Sever's work include Blood Pressure and Hypertension Studies (91 papers), Lipoproteins and Cardiovascular Health (39 papers) and Hormonal Regulation and Hypertension (34 papers). Peter Sever is often cited by papers focused on Blood Pressure and Hypertension Studies (91 papers), Lipoproteins and Cardiovascular Health (39 papers) and Hormonal Regulation and Hypertension (34 papers). Peter Sever collaborates with scholars based in United Kingdom, United States and Sweden. Peter Sever's co-authors include Neil R Poulter, Eoin OʼBrien, Gordon T. McInnes, Hans Wedel, Mark J. Caulfield, Sverre E. Kjeldsen, Rory Collins, Jesper Mehlsen, Markku S. Nieminen and Arni Kristinsson and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Peter Sever

187 papers receiving 16.0k citations

Hit Papers

Prevention of coronary and stroke events with atorvastati... 2003 2026 2010 2018 2003 2005 2010 2015 2004 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
    2003 2.7k citations Peter Sever, Neil R Poulter et al. profile →
  2. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
    2005 1.9k citations Björn Dahlöf, Peter Sever et al. profile →
  3. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
    2010 1.3k citations Eamon Dolan, Peter Sever et al. profile →
  4. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
    2015 735 citations Peter Sever et al. profile →
  5. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
    2004 591 citations Neil R Poulter, Peter Sever et al. BMJ profile →
  6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
    2019 585 citations Robert P. Giugliano, Estella Kanevsky et al. Circulation profile →
  7. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
    2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
  8. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
    2010 480 citations Eamon Dolan, Neil R Poulter et al. profile →
  9. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
    2015 455 citations Neil R Poulter, Peter Sever et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Sever United Kingdom 51 9.8k 7.0k 5.1k 2.5k 1.4k 193 16.8k
Gordon T. McInnes United Kingdom 42 8.6k 0.9× 4.3k 0.6× 5.3k 1.0× 1.8k 0.7× 1.3k 0.9× 123 13.4k
Mark J. Caulfield United Kingdom 50 8.2k 0.8× 6.0k 0.9× 6.2k 1.2× 1.8k 0.7× 1.5k 1.1× 170 17.2k
Gareth Beevers United Kingdom 30 7.7k 0.8× 3.8k 0.5× 4.4k 0.9× 1.5k 0.6× 985 0.7× 60 12.5k
Jan Östergren Sweden 48 14.2k 1.5× 4.7k 0.7× 5.6k 1.1× 1.7k 0.7× 720 0.5× 140 19.7k
Prakash Deedwania United States 65 11.4k 1.2× 5.6k 0.8× 5.9k 1.2× 1.5k 0.6× 538 0.4× 390 19.4k
Barry R. Davis United States 56 13.3k 1.4× 9.4k 1.3× 5.9k 1.2× 3.0k 1.2× 1.3k 0.9× 256 25.7k
Ole Færgeman Denmark 41 5.1k 0.5× 9.9k 1.4× 5.6k 1.1× 2.8k 1.1× 683 0.5× 191 16.3k
James M. McKenney United States 49 5.0k 0.5× 10.2k 1.5× 7.6k 1.5× 3.3k 1.3× 1.4k 1.0× 155 21.1k
Björn Dahlöf Sweden 40 8.8k 0.9× 3.1k 0.4× 4.3k 0.8× 1.3k 0.5× 922 0.7× 104 12.0k
David D. Waters United States 70 10.7k 1.1× 9.1k 1.3× 5.8k 1.1× 1.3k 0.5× 440 0.3× 337 22.3k

Countries citing papers authored by Peter Sever

Since Specialization
Citations

This map shows the geographic impact of Peter Sever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Sever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Sever more than expected).

Fields of papers citing papers by Peter Sever

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Sever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Sever. The network helps show where Peter Sever may publish in the future.

Co-authorship network of co-authors of Peter Sever

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Sever. A scholar is included among the top collaborators of Peter Sever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Sever. Peter Sever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Graham, Colin A., Joanna M. Prasher, Margarita Capel, et al.. (2024). Trends in hypertension prevalence and control in England over the last 3 decades: Health Survey of England 1994-2019. European Heart Journal. 45(Supplement_1).
4.
Wang, Ji‐Guang, et al.. (2023). Amlodipine in the current management of hypertension. Journal of Clinical Hypertension. 25(9). 801–807. 24 indexed citations
5.
Messerli, Franz H., Jana Brguljan, Emrush Rexhaj, et al.. (2021). Lowering systolic blood pressure to 120 mmHg or The Lancet’s true grit. European Heart Journal. 42(21). 2052–2059. 3 indexed citations
6.
Poulter, Neil R, Eamon Dolan, Ajay Gupta, et al.. (2019). Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. American Journal of Cardiovascular Drugs. 19(3). 313–323. 6 indexed citations
7.
Charytan, David M., Marc S. Sabatine, Terje R. Pedersen, et al.. (2019). Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Journal of the American College of Cardiology. 73(23). 2961–2970. 121 indexed citations
8.
Bohula, Erin A., Robert P. Giugliano, Lawrence A. Leiter, et al.. (2018). Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 138(2). 131–140. 193 indexed citations
9.
Bonaca, Marc P., Patrice Nault, Robert P. Giugliano, et al.. (2017). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 137(4). 338–350. 491 indexed citations breakdown →
10.
Murphy, Sabina A., Terje R. Pedersen, Zbigniew Gaciong, et al.. (2017). Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial. Circulation. 3 indexed citations
11.
Sabatine, Marc S., Robert P. Giugliano, Anthony Keech, et al.. (2015). Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal. 173. 94–101. 130 indexed citations
12.
Sever, Peter, Neil R Poulter, Choon Lan Chang, et al.. (2013). Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin. Journal of the American College of Cardiology. 62(8). 717–729. 27 indexed citations
13.
Bangalore, Sripal, Sunil Kumar, Sverre E. Kjeldsen, et al.. (2010). Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. The Lancet Oncology. 12(1). 65–82. 270 indexed citations
14.
Manisty, Charlotte, Jamil Mayet, Robyn J. Tapp, et al.. (2010). Wave Reflection Predicts Cardiovascular Events in Hypertensive Individuals Independent of Blood Pressure and Other Cardiovascular Risk Factors. Journal of the American College of Cardiology. 56(1). 24–30. 82 indexed citations
15.
Chapman, Neil, Joanna Dobson, Björn Dahlöf, et al.. (2007). Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 49(4). 839–845. 437 indexed citations
16.
Ariff, Ben, Andrew Zambanini, Yun Xu, et al.. (2006). Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in Hypertension. Stroke. 37(9). 2381–2384. 38 indexed citations
17.
18.
Stanton, Alice, Jamil Mayet, Peter Sever, et al.. (2001). Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clinical Science. 101(5). 455–464. 34 indexed citations
19.
Sever, Peter. (1999). α-Blockers in Hypertension. Current Medical Research and Opinion. 15(2). 95–103. 12 indexed citations
20.
Poulter, Neil R, Peter Sever, & Simon Thom. (1990). Antihypertensive and adverse biochemical effects of bendrofluazide. BMJ. 300(6737). 1465.2–1465. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gordon T. McInnes Breakdown of academic impact, for papers by Mark J. Caulfield Breakdown of academic impact, for papers by Gareth Beevers Breakdown of academic impact, for papers by Jan Östergren Breakdown of academic impact, for papers by Prakash Deedwania Breakdown of academic impact, for papers by Barry R. Davis Breakdown of academic impact, for papers by Ole Færgeman Breakdown of academic impact, for papers by James M. McKenney Breakdown of academic impact, for papers by Björn Dahlöf Breakdown of academic impact, for papers by David D. Waters
Rankless by CCL
2026